Surfaceome CRISPR screening for SARS-CoV-2 virulent proteins
Surfaceome CRISPR screening for SARS-CoV-2 virulent proteins
批准号:
10892771
负责人:
Sanghyun Lee
金额:
$16.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
未结题
起止时间:
2016-06-01 至 2026-07-31
关键词:
2019-nCoVACE2BindingCOVID-19COVID-19 screeningCRISPR screenCRISPR-mediated transcriptional activationCell membraneCellsCenters of Research ExcellenceComputational BiologyDataFibroblastsHumanLibrariesLungMediatingMembrane ProteinsNamesNorovirusPathologicPhysiologicalPreparationProteinsRecombinantsRoleSARS-CoV-2 entry inhibitorStainsTherapeutic antibodiesVaccinesViralVirulenceVirulentcoronavirus diseasehuman diseasenovelreceptorreceptor bindingscreeningsyndecan-4viral entry inhibitor
中文摘要
严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)是冠状病毒的病原体
英文摘要
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus
disease 19 (COVID-19). Spike protein is the primary antigenic target for COVID vaccines and interfering
with the interface between RBD (Receptor Binding Domain) of spike and ACE2 is the mechanism of
action for the majority of existing therapeutic antibodies, indicating the importance of RBD and its binding
to the cellular receptor for controlling SARS-CoV-2. It is unclear whether there are any intrinsic cellular
proteins that inhibit viral entry of SARS-CoV-2.
Our new preliminary data reveal that cellular entry of SARS-CoV-2 is inhibited by a novel inhibitory cellular
protein, Leucin-rich repeat containing 15 (LRRC15). We generated a focused CRISPR activation
(CRISPRa) library, named surfaceome, that covers all ~6000 known/predicted surface proteins on the
cellular plasma membrane. The surfaceome CRISPRa screening was performed by staining cells with a
recombinant spike protein to identify SARS-CoV-2 binding factors. Strikingly, LRRC15 inhibits
spike-mediated viral entry not only in the same cells, but also in neighboring cells in trans. Expression of
LRRC15 in ACE2+ cells blocked spike-mediated viral entry in ACE2+LRRC15- cells, providing a unique
concept of viral entry inhibition by an inhibitory factor. This result suggests a protective role of LRRC15 in
a physiological context. Our central hypothesis is that human LRRC15 acts as an inhibitory entry factor for
SARS-CoV-2, acting in trans as a decoy receptor expressed in non-susceptible pathological fibroblasts in
the lung. This proposal will explore the mechanism by which LRRC15 inhibits entry of SARS-CoV-2 in
trans through three subaims of Aim 1.
We will leverage the screening platform to identify cellular receptors for secreted virulence proteins of
SARS-CoV-2, Orf3a, Orf7a, and Orf8. Importantly, the same screening platform is validated to be a
efficient platform for secreted virulent proteins. In a separate screening for norovirus secreted virulence
protein (NS1), the surfaceome screening successfully identified Syndecan-4 as a putative cellular receptor
for norovirus NS1 (Li et al., In preparation). In the Aim 2, we will perform a surfaceome screening for
Orf3a, Orf7a, and Orf8 and will discover putative cellular receptors for the secreted virulence proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Entry inhibition of SARS-CoV-2 by human LRRC15
-
批准号:10575888
-
项目类别:
-
资助金额:$21.73万
-
财政年份:2023
-
负责人:Sanghyun Lee
-
依托单位:
Surfaceome CRISPR screening for SARS-CoV-2 virulent proteins
-
批准号:10891755
-
项目类别:
-
资助金额:$19.87万
-
财政年份:2022
-
负责人:Sanghyun Lee
-
依托单位:
A Secreted Viral Protein Determines Norovirus Persistence By Immune Evasion
-
批准号:10219936
-
项目类别:
-
资助金额:$24.5万
-
财政年份:2020
-
负责人:Sanghyun Lee
-
依托单位:
A Secreted Viral Protein Determines Norovirus Persistence By Immune Evasion
-
批准号:10186953
-
项目类别:
-
资助金额:$24.83万
-
财政年份:2020
-
负责人:Sanghyun Lee
-
依托单位:
国内基金
海外基金
登录
查看更多内容
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
-
批准号:JCZRLH202600625
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
-
批准号:2026JJ50619
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:翁春艳
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
-
批准号:Y24H280055
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:颜美秋
-
依托单位:
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
-
批准号:82330111
-
项目类别:重点项目
-
资助金额:220万元
-
批准年份:2023
-
负责人:刘刚
-
依托单位:
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
-
批准号:82373169
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:顾良友
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
-
批准号:32300137
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陈静
-
依托单位:
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
-
批准号:32302080
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:宋田源
-
依托单位:
基于AT2/ACE2/Ang(1-7)/MAS轴调控心脏-血管-血液系统性重构演变规律研究心衰气虚血瘀证及其益气通脉活血化瘀治法生物学基础
-
批准号:82305216
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:姚骏凯
-
依托单位:
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
-
批准号:82305171
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:吴永灿
-
依托单位: